5月6日 - ** 制药公司Madrigal Pharmaceuticals MDGL.O股价上涨5.3%，报529.08美元
** 据伦敦证券交易所集团（LSEG）数据显示，该公司第一季度营收为3.113亿美元，高于分析师预期的3.008亿美元
** Rezdiffra——Madrigal Pharmaceuticals目前唯一上市的治疗MASH（一种脂肪肝疾病）的药物——贡献了第一季度全部营收，销售额同比增长127%
** 公司表示，截至3月31日，已有超过42,250名患者正在使用Rezdiffra，较一年前增长约2.5倍
** 巴克莱表示：“我们对MASH市场的规模依然充满信心，并认为相较于其他中型生物科技公司，MDGL的股价被低估了”
** 计入当日走势，MDGL今年以来累计下跌9.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.